輝瑞PF-08046054啓動III期臨牀適應症為非小細胞肺癌

新浪財經

2025/09/24

藥物臨牀試驗登記與信息公示平台數據顯示，Pfizer Inc./輝瑞投資有限公司/BSP Pharmaceuticals S.p.A的一項在既往接受過治療的程序性細胞死亡配體1 (PD - L1) 陽性非小細胞肺癌(NSCLC) 成人研究參與者中評價PF - 08046054/SGN - PDL1V相比多西他賽的隨機、III期、開放性研究已啓動。臨牀試驗登記號為CTR20253854，首次公示信息...

網頁鏈接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2569070053"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2569070053\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2569070053?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-09-24 12:31","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2569070053","market":"us","top_or_hot":-1,"title":"輝瑞PF-08046054啓動III期臨牀 適應症為非小細胞肺癌","media":"新浪財經","content":"<div>\n<p>藥物臨牀試驗登記與信息公示平台數據顯示，Pfizer Inc./輝瑞投資有限公司/BSP Pharmaceuticals S.p.A的一項在既往接受過治療的程序性細胞死亡配體1 (PD - L1) 陽性非小細胞肺癌(NSCLC) 成人研究參與者中評價PF - 08046054/SGN - PDL1V相比多西他賽的隨機、III期、開放性研究已啓動。臨牀試驗登記號為CTR20253854，首次公示信息...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025092412382897a63026&s=b\">網頁鏈接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>輝瑞PF-08046054啓動III期臨牀 適應症為非小細胞肺癌</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n輝瑞PF-08046054啓動III期臨牀 適應症為非小細胞肺癌\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">新浪財經</strong><span class=\"h-time small\">2025-09-24 12:31</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>藥物臨牀試驗登記與信息公示平台數據顯示，Pfizer Inc./輝瑞投資有限公司/BSP Pharmaceuticals S.p.A的一項在既往接受過治療的程序性細胞死亡配體1 (PD - L1) 陽性非小細胞肺癌(NSCLC) 成人研究參與者中評價PF - 08046054/SGN - PDL1V相比多西他賽的隨機、III期、開放性研究已啓動。臨牀試驗登記號為CTR20253854，首次公示信息...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025092412382897a63026&s=b\">網頁鏈接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025092412382897a63026&s=b\">新浪財經</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B19Z3581.USD","symbol_name":"Legg Mason ClearBridge - Value A Acc USD","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025092412382897a63026&s=b","article_id":"2569070053","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025092412382897a63026&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2569070053","pubTimestamp":1758688260,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"藥物臨床試驗登記與信息公示平台數據顯示，Pfizer Inc./輝瑞投資有限公司/BSP Pharmaceuticals S.p.A的一項在既往接受過治療的程序性細胞死亡配體1  陽性非小細胞肺癌 成人研究參與者中評價PF - 08046054/SGN - PDL1V相比多西他賽的隨機、III期、開放性研究已啓動。本次試驗主要目的為在特定NSCLC研究參與者中，確定PF - 08046054單藥治療與標準治療多西他賽單藥治療相比是否可改善臨床結局。PF - 08046054為生物製品，適應症為非小細胞肺癌。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","BK4592":"伊斯兰概念","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU0122379950.USD":"贝莱德世界健康科学A2","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","III":"信息服务","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4588":"碎股","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU0058720904.USD":"联博国际健康护理基金A","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","LU0234572021.USD":"高盛美国核心股票组合Acc","BK4134":"信息科技咨询与其它服务","BK4007":"制药","SG9999001176.USD":"United Global Healthcare Acc USD","PFE":"辉瑞","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","BK4581":"高盛持仓","BK4599":"减肥药","SG9999002232.USD":"Allianz Global High Payout USD","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","SG9999002224.SGD":"Allianz Global High Payout SGD"},"translate_title":"Pfizer PF-08046054 initiates phase III clinical indication for non-small cell lung cancer","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"III":1.5,"PFE":1.5},"content_text":"藥物臨床試驗登記與信息公示平台數據顯示，Pfizer Inc./輝瑞投資有限公司/BSP Pharmaceuticals S.p.A的一項在既往接受過治療的程序性細胞死亡配體1 (PD - L1) 陽性非小細胞肺癌(NSCLC) 成人研究參與者中評價PF - 08046054/SGN - PDL1V相比多西他賽的隨機、III期、開放性研究已啓動。臨床試驗登記號為CTR20253854，首次公示信息日期為2025年9月24日。該藥物劑型為注射劑，用法為靜脈注射，試驗藥PF - 08046054用法用量為1.5mg/kg 2Q3W AIBW，每次進行約30分鐘的靜脈輸注。本次試驗主要目的為在特定NSCLC研究參與者中，確定PF - 08046054單藥治療與標準治療多西他賽單藥治療相比是否可改善臨床結局。PF - 08046054為生物製品，適應症為非小細胞肺癌。非小細胞肺癌是最常見的肺癌類型，包括腺癌、鱗癌等，症狀有咳嗽、咯血、胸痛等。診斷依靠影像學檢查和病理活檢，治療手段有手術、放化療、靶向治療等。本次試驗主要終點指標包括總生存期(OS)；BICR根據RECIST v1.1評估的PFS。次要終點指標包括BICR根據RECIST v1.1評估的已確認ORR；研究者根據RECIST v1.1評估的PFS、已確認ORR、DOR；不良事件(AE)的類型、發生率、嚴重程度、嚴重性和相關性等。目前，該實驗狀態為進行中（尚未招募），目標入組人數國內102人、國際680人。風險提示：市場有風險，投資需謹慎。本文為AI大模型基於第三方數據庫自動發布，任何在本文出現的信息（包括但不限於個股、評論、預測、圖表、指標、理論、任何形式的表述等）均只作為參考，不構成個人投資建議。受限於第三方數據庫質量等問題，我們無法對數據的真實性及完整性進行分辨或核驗，因此本文內容可能出現不準確、不完整、誤導性的內容或信息，具體以公司公告為準。如有疑問，請聯繫biz@staff.sina.com.cn。責任編輯：小浪快報","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}

輝瑞PF-08046054啓動III期臨牀 適應症為非小細胞肺癌

熱議股票

輝瑞PF-08046054啓動III期臨牀適應症為非小細胞肺癌